Study Advises AstraZeneca, Pfizer Vaccines To Tackle B1.617.2 Variant

A UK Government study has proven 80% effectiveness of Oxford-Astra Zeneca and Pfizer vaccines in treating B1.617.2, the COVID variant first found in India. The discovery, based upon Public Health England reports, also revealed that the two doses of vaccines are 87% effective against B.117 variant, first reported in England. As for the transmissibility, an expert in COVID-19 genomics said B1.617.2 can be 20%-50% more infectious than B.117 variant.